Hodgkin Disease (HD) Banking Study

Trial Information

Hodgkin Disease (HD) Banking Study

OBJECTIVES:

- Establish a biologic specimen repository (of tumor tissue, tissue arrays,
lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and
database linked to clinical features and outcomes from well-characterized cohorts of
children and young adults with Hodgkin's lymphoma.

- Provide specimens from diagnosis, early response evaluation, completion of chemotherapy
and radiotherapy, long-term follow up, and relapse to study prognostic factors for
early response, relapse, long-term outcomes, and identification of new biological
targets for therapy.

OUTLINE: This is a multicenter study.

Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection
of tumor tissue samples at baseline and at relapse or disease progression. Serum and
anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of
course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year
after diagnosis, and at relapse or disease progression.

Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval
clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral
blood samples at relapse or disease progression.

Patients enrolled more than 1 year after completion of treatment undergo collection of tumor
specimens, serum, and anticoagulated peripheral blood samples at time of clinical
evaluation.

PROJECTED ACCRUAL: A total of 1,272 patients will be accrued for this study.